VIATRIS INC. Deferred Tax Liabilities, Net
VIATRIS INC. (VTRS) had Deferred Tax Liabilities, Net of $354.90 million as of 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net
us-gaap:DeferredTaxLiabilities · last filed 2026-02-26
- 2024-12-31: Deferred Tax Liabilities, Net $354.90M.
- 2023-12-31: Deferred Tax Liabilities, Net $1.04B.
- 2022-12-31: Deferred Tax Liabilities, Net $1.51B.
- 2021-12-31: Deferred Tax Liabilities, Net $1.48B.
| Period end | Deferred Tax Liabilities, Net |
|---|---|
| 2024-12-31 | $354.90M 10-K · filed 2026-02-26 |
| 2023-12-31 | $1.04B 10-K · filed 2025-02-27 |
| 2022-12-31 | $1.51B 10-K · filed 2024-02-28 |
| 2021-12-31 | $1.48B 10-K · filed 2023-02-27 |
| 2020-12-31 | $975.80M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |